Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249. Online ahead of print. ABSTRACT KRAS is the most frequently mutated oncogene in lung adenocarcinoma, with G12C …